flumazenil has been researched along with Hepatic Encephalopathy in 109 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the double blind randomized, placebo controlled study, 54 patients with hepatic encephalopathy grade III-IV were randomly assigned to receive either flumazenil 2 mg iv (group A) or placebo (group B); conventional treatment with branched-chain amino acid, saline, glucose, and lactulose was administered in both groups." | 9.09 | Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. ( Balzano, A; Laccetti, M; Lioniello, M; Manes, G; Rabitti, PG; Uomo, G, 2000) |
| "4-1 mg flumazenil results in a modest but rapid improvement in the EEG grading of hepatic encephalopathy and to a moderate but delayed improvement in the clinical grade of hepatic encephalopathy." | 9.08 | Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. ( Benhamou, Y; Cadranel, JF; el Younsi, M; Opolon, P; Pidoux, B; Valla, D; Zylberberg, P, 1995) |
| "To evaluate the beneficial and harmful effects of flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy." | 8.95 | Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. ( Andersen, ML; Gluud, LL; Goh, ET; Morgan, MY, 2017) |
| "We found low quality evidence suggesting a short-term beneficial effect of flumazenil on hepatic encephalopathy in people with cirrhosis, but no evidence of an effect on all-cause mortality." | 8.95 | Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. ( Andersen, ML; Gluud, LL; Goh, ET; Morgan, MY, 2017) |
| " We concluded flumazenil does not reduce mortality in patients with hepatic encephalopathy and it is not clear whether it leads to any clinical improvement because the certainty of the evidence is very low." | 8.95 | Is flumazenil an alternative for the treatment of hepatic encephalopathy? ( Barrera, F; Reyes, D, 2017) |
| "An overview of randomized controlled trials comparing flumazenil and placebo in hepatic encephalopathy in patients with cirrhosis was performed." | 8.81 | Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. ( Bernard, B; Cadranel, JF; Di Martino, V; Goulenok, C; Opolon, P; Poynard, T; Thabut, D, 2002) |
| "Therapeutic modulation of the increased GABAergic tone in chronic hepatic encephalopathy (HE) by the benzodiazepine receptor (BR) antagonist flumazenil (F) has led to conflicting results in humans and animal models for HE." | 7.70 | Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil. ( Legemate, DA; Meyer, HP; Rothuizen, J; van den Brom, W, 1998) |
| "The effect of intravenous administration of flumazenil on hepatic encephalopathy in children with fulminant liver failure is inconsistent." | 7.69 | Flumazenil in the treatment of hepatic encephalopathy in children with fulminant liver failure. ( Devictor, D; Durand, P; Lanchier, C; Navelet, Y; Rousset, A; Tahiri, C, 1995) |
| "The purpose of this report is to describe the use of flumazenil as a diagnostic aid in the differential diagnosis of coma in a patient with an inadvertent overdose of benzodiazepines." | 7.69 | Flumazenil as a diagnostic tool in the differential diagnosis of coma in a critically ill patient. ( McLachlan, RS; Sharpe, MD; Sprenger, H, 1994) |
| " We evaluated the visual EP, brain stem auditory EP, and somatosensory EP (SSEP) and the effect of benzodiazepine receptor antagonist flumazenil in patients with liver cirrhosis." | 7.69 | Evoked potentials and the effect of flumazenil in patients with liver cirrhosis. ( Arik, Z; Kahraman, H; Kesim, G; Onar, M; Ozyilkan, E, 1997) |
| "In animal studies as well as in a few cases in humans, the benzodiazepine antagonist flumazenil has been shown to reverse hepatic encephalopathy." | 7.68 | [Treatment of acute hepatic encephalopathy with flumazenil]. ( Bassoul, B; de La Coussaye, JE; Eledjam, JJ; Saissi, G; Viel, E, 1990) |
| "The effect of flumazenil, a benzodiazepine antagonist, on hepatic encephalopathy was studied in rabbits with acute hepatic failure induced by a two-stage liver devascularization procedure." | 7.68 | Flumazenil does not improve hepatic encephalopathy associated with acute ischemic liver failure in the rabbit. ( de Knegt, RJ; Mechelse, K; Schalm, SW; Terpstra, OT; van der Rijt, CC, 1990) |
| "The effects of the benzodiazepine antagonist flumazenil were studied in 20 episodes of hepatic encephalopathy (HE) in 17 patients with acute (n = 9) or chronic (n = 8) liver failure who had not responded to conventional therapy." | 7.67 | Improvement of hepatic encephalopathy treated with flumazenil. ( Ferenci, P; Gangl, A; Grimm, G; Katzenschlager, R; Laggner, AN; Lenz, K; Madl, C; Schneeweiss, B, 1988) |
| "Treatment of chronic hepatic encephalopathy is difficult." | 5.29 | [Chronic hepatic encephalopathy treated by long-term intravenous administration of flumazenil in ambulatory care]. ( Frappa, B; Paolini, O; Péroux, JL; Rampal, P; Tran, A, 1996) |
| "Flumazenil was not found to induce significant changes in the clinical status or in maps of the cerebral activity of patients with chronic encephalopathy." | 5.28 | [Evaluation of the therapeutic effect of flumazenil in hepatic encephalopathy using cerebral cartography]. ( Bello Mimbrera, G; de la Torre Fernández, JM; de la Torre Gutiérrez, S; García de León, M; Montero Vázquez, J; Torres Salcines, J, 1989) |
| "BZA seems to improve hepatic encephalopathy, especially at an early stage (II)." | 5.27 | Treatment of hepatic encephalopathy (HE) with the benzodiazepine antagonist flumazenil: a pilot study. ( Gyr, K; Meier, R, 1988) |
| "It was concluded that continuous IV infusion of flumazenil had beneficial and safe effects in the treatment of hepatic encephalopathy patients." | 5.10 | The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients. A prospective, randomised, double-blind, placebo-controlled study. ( Aluclu, U; Caliskan, M; Canoruc, F; Canoruc, N; Dursun, M; Ertem, M; Isikdogan, A; Tuzcu, A; Yilmaz, S, 2003) |
| " In the double blind randomized, placebo controlled study, 54 patients with hepatic encephalopathy grade III-IV were randomly assigned to receive either flumazenil 2 mg iv (group A) or placebo (group B); conventional treatment with branched-chain amino acid, saline, glucose, and lactulose was administered in both groups." | 5.09 | Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. ( Balzano, A; Laccetti, M; Lioniello, M; Manes, G; Rabitti, PG; Uomo, G, 2000) |
| "4-1 mg flumazenil results in a modest but rapid improvement in the EEG grading of hepatic encephalopathy and to a moderate but delayed improvement in the clinical grade of hepatic encephalopathy." | 5.08 | Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. ( Benhamou, Y; Cadranel, JF; el Younsi, M; Opolon, P; Pidoux, B; Valla, D; Zylberberg, P, 1995) |
| "To evaluate the beneficial and harmful effects of flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy." | 4.95 | Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. ( Andersen, ML; Gluud, LL; Goh, ET; Morgan, MY, 2017) |
| "We found low quality evidence suggesting a short-term beneficial effect of flumazenil on hepatic encephalopathy in people with cirrhosis, but no evidence of an effect on all-cause mortality." | 4.95 | Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. ( Andersen, ML; Gluud, LL; Goh, ET; Morgan, MY, 2017) |
| " We concluded flumazenil does not reduce mortality in patients with hepatic encephalopathy and it is not clear whether it leads to any clinical improvement because the certainty of the evidence is very low." | 4.95 | Is flumazenil an alternative for the treatment of hepatic encephalopathy? ( Barrera, F; Reyes, D, 2017) |
| "Flumazenil had a significant beneficial effect on short-term improvement of hepatic encephalopathy in patients with cirrhosis and a highly favourable prognosis." | 4.82 | Benzodiazepine receptor antagonists for hepatic encephalopathy. ( Als-Nielsen, B; Gluud, C; Gluud, LL, 2004) |
| "Flumazenil had no significant effect on recovery or survival from hepatic encephalopathy." | 4.81 | Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. ( Als-Nielsen, B; Gluud, C; Kjaergard, LL, 2001) |
| "An overview of randomized controlled trials comparing flumazenil and placebo in hepatic encephalopathy in patients with cirrhosis was performed." | 4.81 | Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. ( Bernard, B; Cadranel, JF; Di Martino, V; Goulenok, C; Opolon, P; Poynard, T; Thabut, D, 2002) |
| "For the first time a causal treatment of hepatic encephalopathy may be possible by the benzodiazepine antagonist flumazenil." | 4.77 | [Benzodiazepine antagonists in the treatment of heptic encephalopathy]. ( Ferenci, P; Grimm, G, 1989) |
| "To assess the possible implication of the allosteric coupling of different modulatory sites at the GABA-A receptor complex in hepatic encephalopathy (HE), we investigated in autopsied frontal cortex of six cirrhotic patients and six appropriately-matched controls, the modulatory effects of the benzodiazepine site agonist flunitrazepam on the binding of [3H]muscimol and the effect of the neurosteroid site agonist allopregnanolone (5alpha-pregnan-3alpha-ol-20-one) on the binding of [3H]muscimol and [3H]flunitrazepam." | 3.72 | Normal coupling of brain benzodiazepine and neurosteroid modulatory sites on the GABA-A receptor complex in human hepatic encephalopathy. ( Ahboucha, S; Butterworth, RF; Chatauret, N; Desjardins, P; Pomier-Layrargues, G, 2003) |
| "Therapeutic modulation of the increased GABAergic tone in chronic hepatic encephalopathy (HE) by the benzodiazepine receptor (BR) antagonist flumazenil (F) has led to conflicting results in humans and animal models for HE." | 3.70 | Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil. ( Legemate, DA; Meyer, HP; Rothuizen, J; van den Brom, W, 1998) |
| "The effect of intravenous administration of flumazenil on hepatic encephalopathy in children with fulminant liver failure is inconsistent." | 3.69 | Flumazenil in the treatment of hepatic encephalopathy in children with fulminant liver failure. ( Devictor, D; Durand, P; Lanchier, C; Navelet, Y; Rousset, A; Tahiri, C, 1995) |
| "The purpose of this report is to describe the use of flumazenil as a diagnostic aid in the differential diagnosis of coma in a patient with an inadvertent overdose of benzodiazepines." | 3.69 | Flumazenil as a diagnostic tool in the differential diagnosis of coma in a critically ill patient. ( McLachlan, RS; Sharpe, MD; Sprenger, H, 1994) |
| " We evaluated the visual EP, brain stem auditory EP, and somatosensory EP (SSEP) and the effect of benzodiazepine receptor antagonist flumazenil in patients with liver cirrhosis." | 3.69 | Evoked potentials and the effect of flumazenil in patients with liver cirrhosis. ( Arik, Z; Kahraman, H; Kesim, G; Onar, M; Ozyilkan, E, 1997) |
| "Two benzodiazepine-receptor partial inverse agonists (Ro 15-4513, Ro 15-3505) and one benzodiazepine-receptor antagonist (flumazenil) were administered to rats with hepatic encephalopathy due to acute liver ischemia." | 3.68 | The effects of benzodiazepine-receptor antagonists and partial inverse agonists on acute hepatic encephalopathy in the rat. ( Bosman, DK; Chamuleau, RA; de Haan, JG; Maas, MA; van den Buijs, CA, 1991) |
| "Brain concentrations of substances inhibiting the binding of [3H]flumazenil to its receptors are increased in some patients with hepatic encephalopathy due to fulminant hepatic failure." | 3.68 | Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. ( Basile, AS; Harrison, PM; Hughes, RD; Jones, EA; Murata, Y; Pannell, L; Skolnick, P; Williams, R, 1991) |
| "In animal studies as well as in a few cases in humans, the benzodiazepine antagonist flumazenil has been shown to reverse hepatic encephalopathy." | 3.68 | [Treatment of acute hepatic encephalopathy with flumazenil]. ( Bassoul, B; de La Coussaye, JE; Eledjam, JJ; Saissi, G; Viel, E, 1990) |
| "The effect of flumazenil, a benzodiazepine antagonist, on hepatic encephalopathy was studied in rabbits with acute hepatic failure induced by a two-stage liver devascularization procedure." | 3.68 | Flumazenil does not improve hepatic encephalopathy associated with acute ischemic liver failure in the rabbit. ( de Knegt, RJ; Mechelse, K; Schalm, SW; Terpstra, OT; van der Rijt, CC, 1990) |
| "The involvement of the gamma-aminobutyric acidA (GABAA) receptor complex in the pathogenesis of hepatic encephalopathy was examined in thioacetamide-treated rats with fulminant hepatic failure." | 3.67 | GABAA receptor complex in an experimental model of hepatic encephalopathy: evidence for elevated levels of an endogenous benzodiazepine receptor ligand. ( Basile, AS; Gammal, SH; Jones, EA; Skolnick, P, 1989) |
| "The role of the GABA-benzodiazepine receptor complex in the pathogenesis of hepatic encephalopathy was investigated by recording the electrophysiological responses of single cerebellar Purkinje neurons from rabbits with hepatic encephalopathy due to galactosamine-induced fulminant hepatic failure." | 3.67 | Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy. ( Basile, AS; Gammal, SH; Jones, EA; Mullen, KD; Skolnick, P, 1988) |
| "The effects of the benzodiazepine antagonist flumazenil were studied in 20 episodes of hepatic encephalopathy (HE) in 17 patients with acute (n = 9) or chronic (n = 8) liver failure who had not responded to conventional therapy." | 3.67 | Improvement of hepatic encephalopathy treated with flumazenil. ( Ferenci, P; Gangl, A; Grimm, G; Katzenschlager, R; Laggner, AN; Lenz, K; Madl, C; Schneeweiss, B, 1988) |
| "Flumazenil was well tolerated." | 2.68 | Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. ( Amrein, R; Boulétreau, P; Fleig, WE; Gatta, A; Groeneweg, M; Gyr, K; Häussler, J; Holstege, A; Meier, R; Pomier-Layrargues, G; Schalm, SW; Scollo-Lavizzari, G; Ventura, E; Williams, R; Yoo, Y; Zeneroli, ML, 1996) |
| "Ten patients with sub-clinical or latent hepatic encephalopathy (LHE) and ten normal controls were cognitively assessed pre- and post-infusion of 0." | 2.68 | Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy. ( Bzeizi, K; Gooday, R; Hayes, PC; O'Carroll, RE, 1995) |
| "Seventy-seven cirrhotic patients in hepatic coma were evaluated." | 2.67 | Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. ( Butterworth, RF; D'Amour, M; Gagnon, S; Giguère, JF; Lavoie, J; Perney, P; Pomier-Layrargues, G; Wells, J, 1994) |
| "Pharmacologic management of hepatic encephalopathy includes a broad range of therapies." | 2.66 | Pharmacologic Management of Hepatic Encephalopathy. ( Mahpour, NY; Pioppo-Phelan, L; Reja, M; Rustgi, VK; Tawadros, A, 2020) |
| "He was treated for hepatic encephalopathy with complete recovery and resolution of the neurologic findings." | 2.46 | Reversible hepatic decerebration: a case report and review of the literature. ( Antoun, SA; Delgado, F; Saad, D; Ta, H; Wehbe, E, 2010) |
| "Therapeutic management in hepatic encephalopathy depends on its etiology as well as progression degree." | 2.41 | [Therapeutic management of hepatic encephalopathy]. ( Helewski, KJ; Konecki, JJ; Kowalczyk-Ziomek, GI, 2002) |
| "Hepatic encephalopathy is a complex neuropsychiatric syndrome associated with acute, subacute and chronic liver failure, involving increased neural inhibition by activation of the GABA/benzodiazepine inhibitory neurotransmitter system." | 2.38 | Flumazenil in the treatment of portal systemic encephalopathy--an overview. ( Gyr, K; Meier, R, 1991) |
| "Flumazenil has been studied for a variety of indications, including as an antidote to benzodiazepine overdose and for awakening of comatose patients, reversal of sedation after surgery and in critically ill patients, and management of hepatic encephalopathy." | 2.38 | Flumazenil: a benzodiazepine antagonist. ( Hoffman, EJ; Warren, EW, 1993) |
| "In animals and human beings with hepatic encephalopathy, however, benzodiazepine receptor antagonists have induced amelioration of the encephalopathy, and an endogenous substance that competitively binds to benzodiazepine receptors has been found in cerebrospinal fluid." | 2.37 | Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy? ( Bassett, ML; Jones, EA; Martin, JV; Mendelson, WB; Mullen, KD, 1988) |
| " The oral route is optimized by dosing every hour until stool evacuation appears." | 1.31 | Hepatic Encephalopathy. ( Blei, AT; Córdoba, J, 2001) |
| "Treatment of chronic hepatic encephalopathy is difficult." | 1.29 | [Chronic hepatic encephalopathy treated by long-term intravenous administration of flumazenil in ambulatory care]. ( Frappa, B; Paolini, O; Péroux, JL; Rampal, P; Tran, A, 1996) |
| "When treated with flumazenil all signs of encephalopathy abated in spite of an unrestricted dietary intake of protein." | 1.28 | Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. ( Ferenci, P; Gangl, A; Grimm, G; Meryn, S, 1989) |
| "Flumazenil was not found to induce significant changes in the clinical status or in maps of the cerebral activity of patients with chronic encephalopathy." | 1.28 | [Evaluation of the therapeutic effect of flumazenil in hepatic encephalopathy using cerebral cartography]. ( Bello Mimbrera, G; de la Torre Fernández, JM; de la Torre Gutiérrez, S; García de León, M; Montero Vázquez, J; Torres Salcines, J, 1989) |
| "Hepatic encephalopathy is ameliorated by drugs acting on the central GABAA-benzodiazepine receptor complex." | 1.28 | Beneficial effect of pharmacological modulation of the GABAA-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. ( Druml, W; Ferenci, P; Püspök, A; Steindl, P, 1991) |
| "Based on the reversal of hepatic encephalopathy in animal models with administration of specific benzodiazepine receptor antagonists, it has been postulated that this syndrome may be mediated by an endogenous benzodiazepine-like compound." | 1.28 | Evidence for the presence of a benzodiazepine receptor binding substance in cerebrospinal fluid of a rabbit model of hepatic encephalopathy. ( Jones, EA; Kaminsky-Russ, K; Martin, JV; Mendelson, WB; Mullen, KD, 1989) |
| "Recently it was suggested that hepatic encephalopathy (HE) is mediated by an increased GABA-ergic tone." | 1.28 | Benzodiazepine antagonist in the treatment of human hepatic encephalopathy. ( Ferenci, P; Grimm, G, 1990) |
| "The evolution of hepatic encephalopathy in this model was sufficiently slow to readily permit the staging of the syndrome." | 1.28 | Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. ( Basile, AS; Gammal, SH; Geller, D; Jones, EA; Skolnick, P, 1990) |
| "Rabbits with hepatic encephalopathy exhibited increased resistance to the convulsive effects of bicuculline." | 1.27 | Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABAA-benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. ( Bassett, ML; Jones, EA; Mullen, KD; Skolnick, P, 1987) |
| "BZA seems to improve hepatic encephalopathy, especially at an early stage (II)." | 1.27 | Treatment of hepatic encephalopathy (HE) with the benzodiazepine antagonist flumazenil: a pilot study. ( Gyr, K; Meier, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (19.27) | 18.7374 |
| 1990's | 56 (51.38) | 18.2507 |
| 2000's | 24 (22.02) | 29.6817 |
| 2010's | 6 (5.50) | 24.3611 |
| 2020's | 2 (1.83) | 2.80 |
| Authors | Studies |
|---|---|
| Mahpour, NY | 1 |
| Pioppo-Phelan, L | 1 |
| Reja, M | 1 |
| Tawadros, A | 1 |
| Rustgi, VK | 1 |
| Alimirah, M | 1 |
| Sadiq, O | 1 |
| Gordon, SC | 1 |
| Goh, ET | 2 |
| Andersen, ML | 2 |
| Morgan, MY | 2 |
| Gluud, LL | 3 |
| Reyes, D | 1 |
| Barrera, F | 1 |
| da Silva, VC | 1 |
| Bittencourt, PL | 1 |
| Pinho, S | 1 |
| Cavalcanti, AR | 1 |
| Zollinger, CC | 1 |
| García Martínez, R | 1 |
| Córdoba Cardona, J | 1 |
| Butterworth, RF | 9 |
| Wehbe, E | 1 |
| Saad, D | 1 |
| Delgado, F | 1 |
| Ta, H | 1 |
| Antoun, SA | 1 |
| Romero-Gómez, M | 1 |
| Foster, KJ | 1 |
| Lin, S | 1 |
| Turck, CJ | 1 |
| Helewski, KJ | 1 |
| Kowalczyk-Ziomek, GI | 1 |
| Konecki, JJ | 1 |
| Dursun, M | 1 |
| Caliskan, M | 1 |
| Canoruc, F | 1 |
| Aluclu, U | 1 |
| Canoruc, N | 1 |
| Tuzcu, A | 1 |
| Yilmaz, S | 1 |
| Isikdogan, A | 1 |
| Ertem, M | 1 |
| Ruscito, BJ | 1 |
| Harrison, NL | 1 |
| Quero Guillén, JC | 1 |
| Carmona Soria, I | 1 |
| García Montes, JM | 1 |
| Jiménez Sáenz, M | 1 |
| Herrerías Gutiérrez, JM | 1 |
| Ahboucha, S | 4 |
| Desjardins, P | 1 |
| Chatauret, N | 1 |
| Pomier-Layrargues, G | 5 |
| Wettstein, M | 1 |
| Häussinger, D | 1 |
| Als-Nielsen, B | 2 |
| Gluud, C | 2 |
| Romero Gómez, M | 1 |
| Bautista, JD | 1 |
| Grande, L | 1 |
| Ramos Guerrero, RM | 1 |
| Sánchez Muñoz, D | 1 |
| Araqi, F | 1 |
| Layrargues, GP | 2 |
| Cortelli, P | 1 |
| Avallone, R | 1 |
| Baraldi, M | 1 |
| Zeneroli, ML | 2 |
| Mandrioli, J | 1 |
| Corsi, L | 1 |
| Riva, R | 1 |
| Tinuper, P | 1 |
| Lugaresi, E | 1 |
| Baruzzi, A | 1 |
| Montagna, P | 1 |
| Coyne, L | 1 |
| Hirakawa, R | 1 |
| Halliwell, RF | 1 |
| Scollo-Lavizzari, G | 3 |
| Cadranel, JF | 2 |
| el Younsi, M | 1 |
| Pidoux, B | 2 |
| Zylberberg, P | 2 |
| Benhamou, Y | 1 |
| Valla, D | 2 |
| Opolon, P | 3 |
| Gooday, R | 1 |
| Hayes, PC | 1 |
| Bzeizi, K | 1 |
| O'Carroll, RE | 1 |
| Perney, P | 3 |
| Devictor, D | 1 |
| Tahiri, C | 1 |
| Lanchier, C | 1 |
| Navelet, Y | 1 |
| Durand, P | 1 |
| Rousset, A | 1 |
| Mullen, KD | 6 |
| Sterling, RK | 1 |
| Shiffman, ML | 1 |
| Schubert, ML | 1 |
| Bruha, R | 1 |
| Marecek, Z | 1 |
| Brodanova, M | 1 |
| Votruba, M | 1 |
| Sprenger, H | 1 |
| Sharpe, MD | 1 |
| McLachlan, RS | 1 |
| Jones, EA | 16 |
| Basile, AS | 8 |
| Yurdaydin, C | 1 |
| Skolnich, P | 1 |
| Giguère, JF | 1 |
| Lavoie, J | 2 |
| Gagnon, S | 1 |
| D'Amour, M | 1 |
| Wells, J | 1 |
| Hoffman, EJ | 1 |
| Warren, EW | 1 |
| Howard, CD | 1 |
| Seifert, CF | 1 |
| Plauth, M | 1 |
| Egberts, EH | 1 |
| Groeneweg, M | 2 |
| Gyr, K | 5 |
| Amrein, R | 2 |
| Williams, R | 3 |
| Yoo, JY | 1 |
| Schalm, SW | 3 |
| Péroux, JL | 1 |
| Paolini, O | 1 |
| Tran, A | 1 |
| Frappa, B | 1 |
| Rampal, P | 1 |
| McDonald, JW | 1 |
| Bautista, RE | 1 |
| Gutmann, DH | 1 |
| Meier, R | 4 |
| Häussler, J | 1 |
| Boulétreau, P | 1 |
| Fleig, WE | 1 |
| Gatta, A | 2 |
| Holstege, A | 1 |
| Ventura, E | 1 |
| Yoo, Y | 1 |
| McArdle, P | 1 |
| Penning, DH | 1 |
| Dexter, F | 1 |
| Reynolds, JD | 1 |
| Macdonald, GA | 1 |
| Frey, KA | 1 |
| Agranoff, BW | 1 |
| Minoshima, S | 1 |
| Koeppe, RA | 1 |
| Kuhl, DE | 1 |
| Shulkin, BL | 1 |
| Lucey, MR | 1 |
| Ozyilkan, E | 1 |
| Kahraman, H | 1 |
| Onar, M | 1 |
| Kesim, G | 1 |
| Arik, Z | 1 |
| Weissenborn, K | 1 |
| Amodio, P | 1 |
| Marchetti, P | 1 |
| Del Piccolo, F | 1 |
| Beghi, A | 1 |
| Comacchio, F | 1 |
| Carraro, P | 1 |
| Campo, G | 1 |
| Baruzzo, L | 1 |
| Marchiori, C | 1 |
| Bañares, R | 1 |
| Carneros, JA | 1 |
| Rincón, D | 1 |
| Barbaro, G | 2 |
| Di Lorenzo, G | 2 |
| Soldini, M | 2 |
| Giancaspro, G | 1 |
| Bellomo, G | 2 |
| Belloni, G | 2 |
| Grisorio, B | 2 |
| Annese, M | 2 |
| Bacca, D | 2 |
| Francavilla, R | 1 |
| Barbarini, G | 2 |
| Mousseau, DD | 1 |
| Fabbro-Peray, P | 1 |
| Blanc, F | 1 |
| Meyer, HP | 1 |
| Legemate, DA | 1 |
| van den Brom, W | 1 |
| Rothuizen, J | 1 |
| Marziali, M | 1 |
| Hammond, JB | 1 |
| Ahmad, F | 1 |
| Amaral, OB | 1 |
| Quevedo, J | 1 |
| Walz, R | 1 |
| Kapczinski, F | 1 |
| Blei, AT | 2 |
| Elkjaer, JM | 1 |
| Jensen, TU | 1 |
| Emborg, J | 1 |
| Sand, P | 1 |
| Kavvadias, D | 1 |
| Feineis, D | 1 |
| Riederer, P | 1 |
| Schreier, P | 1 |
| Kleinschnitz, M | 1 |
| Czygan, FC | 1 |
| Abou-Mandour, A | 1 |
| Bringmann, G | 1 |
| Beckmann, H | 1 |
| Larsen, FS | 1 |
| Córdoba, J | 1 |
| Laccetti, M | 1 |
| Manes, G | 1 |
| Uomo, G | 1 |
| Lioniello, M | 1 |
| Rabitti, PG | 1 |
| Balzano, A | 1 |
| Kjaergard, LL | 1 |
| Giger-Mateeva, VI | 1 |
| Reits, D | 1 |
| Riemslag, FC | 1 |
| Liberov, B | 1 |
| Spekrijse, H | 1 |
| Koczorek, M | 1 |
| Goulenok, C | 1 |
| Bernard, B | 1 |
| Thabut, D | 1 |
| Di Martino, V | 1 |
| Poynard, T | 1 |
| Buchali, K | 1 |
| Seebach, J | 1 |
| Jost, R | 1 |
| Sacristán, JA | 1 |
| Soto, J | 1 |
| Francis, D | 1 |
| Sánchez, R | 1 |
| Hughes, RD | 1 |
| Harrison, PM | 1 |
| Murata, Y | 1 |
| Pannell, L | 1 |
| Skolnick, P | 7 |
| Bosman, DK | 1 |
| van den Buijs, CA | 1 |
| de Haan, JG | 1 |
| Maas, MA | 1 |
| Chamuleau, RA | 1 |
| Steindl, P | 1 |
| Püspök, A | 1 |
| Druml, W | 2 |
| Ferenci, P | 6 |
| Baker, BL | 1 |
| Morrow, AL | 1 |
| Vergalla, J | 1 |
| Paul, SM | 1 |
| Castells, A | 1 |
| Navasa, M | 1 |
| Mas, A | 1 |
| Rodés, J | 1 |
| Scholer, A | 1 |
| Frenkel, AL | 1 |
| Hermant, JL | 2 |
| Blaise, M | 1 |
| Volter, F | 1 |
| Pourriat, JL | 1 |
| Grimm, G | 5 |
| Gammal, SH | 5 |
| Viel, E | 1 |
| de La Coussaye, JE | 1 |
| Bassoul, B | 1 |
| Saissi, G | 1 |
| Eledjam, JJ | 1 |
| Marsepoil, T | 1 |
| Ho, P | 1 |
| Blin, F | 1 |
| Levesque, P | 1 |
| Geller, D | 1 |
| Pomier Layrargues, G | 1 |
| Rothstein, JD | 1 |
| Olasmaa, M | 1 |
| Meier, PJ | 2 |
| Bansky, G | 2 |
| Pintanel, T | 1 |
| Font, MM | 1 |
| García-Guasch, R | 1 |
| van der Rijt, CC | 1 |
| de Knegt, RJ | 1 |
| Terpstra, OT | 1 |
| Mechelse, K | 1 |
| Meryn, S | 1 |
| Gangl, A | 2 |
| Bello Mimbrera, G | 1 |
| García de León, M | 1 |
| de la Torre Gutiérrez, S | 1 |
| Montero Vázquez, J | 1 |
| Torres Salcines, J | 1 |
| de la Torre Fernández, JM | 1 |
| Chesta, J | 1 |
| Brahm, J | 1 |
| Poniachik, J | 1 |
| Riederer, E | 1 |
| Walser, H | 1 |
| Ziegler, WH | 1 |
| Schmid, M | 1 |
| Martin, JV | 2 |
| Mendelson, WB | 2 |
| Kaminsky-Russ, K | 1 |
| Andresen, M | 1 |
| Arrese, M | 1 |
| Dougnac, A | 1 |
| Godoy, J | 1 |
| Prat, G | 1 |
| Chianale, J | 1 |
| Klotz, U | 1 |
| Walker, S | 1 |
| Bassett, ML | 2 |
| Katzenschlager, R | 2 |
| Holzner, F | 1 |
| Schneeweiss, B | 2 |
| Laggner, A | 1 |
| Lenz, K | 2 |
| Madl, C | 2 |
| Burke, DA | 1 |
| Mitchell, KW | 1 |
| al Mardini, H | 1 |
| Record, CO | 1 |
| Laggner, AN | 1 |
| Sutherland, LR | 1 |
| Minuk, GY | 1 |
| Martin, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chinese Chronic Liver Failure Consortium Acute-on-Chronic Liver Disease and Failure Study --a Prospective Multi-center Study in China, the Largest Hepatitis B Virus High-endemic Region.[NCT02457637] | 2,600 participants (Actual) | Observational | 2015-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
be collected and reported at 28 or last visit before discharge (NCT02457637)
Timeframe: Up to 28 days
| Intervention | mg/dL (Median) |
|---|---|
| Acute-on-Chronic Liver Disease | 9.3 |
The appearance and number of organ failure（including liver, coagulation, renal, circulation, brain, respiratory system） will be evaluated and reported at 1, 4, 7, 14, 21 and 28 days (or last visit)during patients' hospitalization. (NCT02457637)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute-on-Chronic Liver Disease | 261 |
Mortality will be respectively calculated together with the liver transplantation rate (as the rate of ''incidence'')and independently (as the ''liver transplantation free mortality'') respectively. (NCT02457637)
Timeframe: up to 180 days
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 180-day mortality rate | 180-day liver transplantation rate | 180-day liver transplantation free mortality' | |
| Acute-on-Chronic Liver Disease Inpatients | 403 | 177 | 403 |
liver-transplantation free mortality refers to number of participants who died in the absence of receiving a liver transplant divided by number of participants without liver transplant. (NCT02457637)
Timeframe: up to 28 days
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 28-day Mortality | 28-day Liver Transplantation Rate at 28 days | 28-day liver transplantation free mortality | |
| Acute-on-Chronic Liver Disease | 74 | 124 | 74 |
liver-transplantation free mortality refers to number of participants who died in the absence of receiving a liver transplant divided by number of participants without liver transplant. (NCT02457637)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 90-day mortality rate | 90-day liver transplantation rate | 90-day liver transplantation free mortality | |
| Acute-on-Chronic Liver Disease Inpatients | 333 | 171 | 333 |
39 reviews available for flumazenil and Hepatic Encephalopathy
| Article | Year |
|---|---|
Pharmacologic Management of Hepatic Encephalopathy.
Topics: Acarbose; Amino Acids, Branched-Chain; Anti-Bacterial Agents; Dipeptides; Fecal Microbiota Transplan | 2020 |
Novel Therapies in Hepatic Encephalopathy.
Topics: Acetylcarnitine; Albumins; Ammonia; Dipeptides; Fecal Microbiota Transplantation; Flumazenil; GABA M | 2020 |
Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Topics: Acute Disease; Antidotes; Cause of Death; Chronic Disease; Flumazenil; GABA Modulators; GABA-A Recep | 2017 |
Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Topics: Cause of Death; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Placeb | 2017 |
Is flumazenil an alternative for the treatment of hepatic encephalopathy?
Topics: Databases, Factual; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Humans; Randomized Controll | 2017 |
[Update on the management of hepatic encephalopathy].
Topics: Aged; Ammonia; Anti-Bacterial Agents; Antidotes; Clinical Trials as Topic; Dialysis; Flumazenil; GAB | 2008 |
Pathophysiology of hepatic encephalopathy: studies in autopsied brain tissue from hepatic coma patients.
Topics: Amino Acids; Animals; Astrocytes; Biogenic Amines; Brain; Brain Chemistry; Catecholamines; Flumazeni | 1990 |
Brain GABA and benzodiazepine receptors in hepatic encephalopathy.
Topics: Animals; Astrocytes; Benzodiazepines; Carrier Proteins; Clinical Trials as Topic; Drug Evaluation, P | 1990 |
Reversible hepatic decerebration: a case report and review of the literature.
Topics: Alcoholism; Decerebrate State; Flumazenil; Hepatic Encephalopathy; Humans; Liver Cirrhosis, Alcoholi | 2010 |
Pharmacotherapy of hepatic encephalopathy in cirrhosis.
Topics: Ammonia; Anti-Bacterial Agents; Fluid Therapy; Flumazenil; Hepatic Encephalopathy; Humans; Intestina | 2010 |
Current and emerging strategies for treating hepatic encephalopathy.
Topics: Acarbose; Anti-Bacterial Agents; Carnitine; Dyskinesias; Electroencephalography; Flumazenil; GABA Mo | 2010 |
[Therapeutic management of hepatic encephalopathy].
Topics: Anti-Bacterial Agents; Disease Progression; Flumazenil; Hepatic Encephalopathy; Humans; Lactulose; L | 2002 |
[Hepatic encephalopathy--therapy].
Topics: Administration, Oral; Ammonia; Anti-Bacterial Agents; Diet, Protein-Restricted; Dipeptides; Flumazen | 2003 |
Benzodiazepine receptor antagonists for hepatic encephalopathy.
Topics: Acute Disease; Antidotes; Chronic Disease; Flumazenil; GABA Modulators; GABA-A Receptor Antagonists; | 2004 |
[New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects].
Topics: Ammonia; Brain; Brain Edema; Dipeptides; Flumazenil; Glutaminase; Glutamine; Hepatic Encephalopathy; | 2004 |
Endozepines in recurrent stupor.
Topics: Coma; Diazepam Binding Inhibitor; Electroencephalography; Flumazenil; Hepatic Encephalopathy; Humans | 2005 |
[Hepatic encephalopathy. Physiopathology and treatment].
Topics: Amino Acids; Anti-Bacterial Agents; Drug Therapy, Combination; Flumazenil; Hepatic Encephalopathy; H | 1994 |
Do benzodiazepine ligands contribute to hepatic encephalopathy?
Topics: Animals; Azides; Benzodiazepines; Benzodiazepinones; Disease Models, Animal; Flumazenil; GABA-A Rece | 1993 |
Flumazenil: a benzodiazepine antagonist.
Topics: Anesthesia; Benzodiazepines; Drug Interactions; Drug Overdose; Flumazenil; Hepatic Encephalopathy; H | 1993 |
Flumazenil in the treatment of hepatic encephalopathy.
Topics: Clinical Trials as Topic; Flumazenil; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans | 1993 |
[What is guaranteed in the therapy of hepatic encephalopathy?].
Topics: Amino Acids, Branched-Chain; Anti-Bacterial Agents; Combined Modality Therapy; Disaccharides; Flumaz | 1993 |
Neurology and the liver.
Topics: Ammonia; Brain Edema; Cholestasis; Diagnosis, Differential; Fatigue; Flumazenil; GABA Modulators; He | 1997 |
[New treatments of hepatic encephalopathy].
Topics: Amino Acids, Branched-Chain; Animals; Benzoates; Benzoic Acid; Clinical Trials as Topic; Electrocard | 1998 |
Hepatic encephalopathy and role of antibenzodiazepines.
Topics: Flumazenil; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Hepatic Encephal | 1998 |
Brain edema and portal-systemic encephalopathy.
Topics: Brain; Brain Edema; Flumazenil; Glutamine; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosi | 2000 |
[Treatment of hepatic encephalopathy with flumazenil].
Topics: Antidotes; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Humans; Prognosis | 2000 |
Naturally occurring benzodiazepines: current status of research and clinical implications.
Topics: Animals; Anxiety; Benzodiazepines; Brain; Chromatography, High Pressure Liquid; Epilepsy; Flumazenil | 2000 |
Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy.
Topics: Acute Disease; Antidotes; Chronic Disease; Flumazenil; GABA Modulators; GABA-A Receptor Antagonists; | 2001 |
Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis.
Topics: Coma; Double-Blind Method; Electroencephalography; Female; Flumazenil; Hepatic Encephalopathy; Human | 2002 |
The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands.
Topics: Ammonia; Animals; Disease Models, Animal; Flumazenil; Hepatic Encephalopathy; Humans; Ligands; Neuro | 1991 |
Flumazenil in the treatment of portal systemic encephalopathy--an overview.
Topics: Animals; Flumazenil; Hepatic Encephalopathy; Humans | 1991 |
Flumazenil: potential implications for hepatic encephalopathy.
Topics: Animals; Flumazenil; Hepatic Encephalopathy; Humans | 1990 |
Benzodiazepine receptors and hepatic encephalopathy.
Topics: Animals; Flumazenil; Hepatic Encephalopathy; Humans; Receptors, GABA-A | 1990 |
Benzodiazepine receptor ligands and the syndrome of hepatic encephalopathy.
Topics: Flumazenil; Hepatic Encephalopathy; Humans; Ligands; Receptors, GABA-A; Synaptic Transmission; Syndr | 1990 |
Endogenous GABAergic modulators in the pathogenesis of hepatic encephalopathy.
Topics: Animals; Benzodiazepines; Diazepam Binding Inhibitor; Flumazenil; Hepatic Encephalopathy; Humans; Ne | 1990 |
[Current possibilities in the therapy of hepatic encephalopathy].
Topics: Combined Modality Therapy; Flumazenil; Hepatic Encephalopathy; Humans; Neural Inhibition; Receptors, | 1990 |
[Benzodiazepine antagonists in the treatment of heptic encephalopathy].
Topics: Animals; Anti-Anxiety Agents; Brain; Flumazenil; Hepatic Encephalopathy; Humans; Receptors, GABA-A | 1989 |
Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy?
Topics: Benzodiazepines; Flumazenil; Hepatic Encephalopathy; Humans; Ligands; Pyrazoles; Receptors, GABA-A; | 1988 |
Hepatic encephalopathy: new light on an old problem.
Topics: Flumazenil; Hepatic Encephalopathy; Humans | 1988 |
13 trials available for flumazenil and Hepatic Encephalopathy
| Article | Year |
|---|---|
The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients. A prospective, randomised, double-blind, placebo-controlled study.
Topics: Adult; Aged; Ambulatory Care; Double-Blind Method; Female; Flumazenil; GABA Modulators; Hepatic Ence | 2003 |
Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study.
Topics: Adult; Aged; Double-Blind Method; Female; Flumazenil; Hepatic Encephalopathy; Humans; Infusions, Par | 1995 |
Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy.
Topics: Carrier Proteins; Cognition; Diazepam Binding Inhibitor; Female; Flumazenil; GABA-A Receptor Antagon | 1995 |
Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial.
Topics: Adolescent; Adult; Aged; Benzodiazepines; Double-Blind Method; Female; Flumazenil; GABA-A Receptor A | 1994 |
Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo-controlled multicentre trial.
Topics: Adult; Aged; Double-Blind Method; Electroencephalography; Female; Flumazenil; Hepatic Encephalopathy | 1996 |
Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study.
Topics: Chronic Disease; Double-Blind Method; Electroencephalography; Female; Flumazenil; Hepatic Encephalop | 1996 |
The effect of flumazenil on subclinical psychometric or neurophysiological alterations in cirrhotic patients: a double-blind placebo-controlled study.
Topics: Cognition; Cognition Disorders; Double-Blind Method; Evoked Potentials, Auditory, Brain Stem; Female | 1997 |
Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study.
Topics: Adult; Aged; Benzodiazepines; Cross-Over Studies; Double-Blind Method; Female; Flumazenil; GABA Modu | 1998 |
Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study.
Topics: Adult; Anti-Anxiety Agents; Antidotes; Cross-Over Studies; Double-Blind Method; Electroencephalograp | 1998 |
Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study.
Topics: Coma; Double-Blind Method; Female; Flumazenil; GABA Modulators; Hemorrhage; Hepatic Encephalopathy; | 2000 |
Visual event-related potentials in cirrhotic patients without overt encephalopathy: the effects of flumazenil.
Topics: Adult; Arousal; Double-Blind Method; Electroencephalography; Event-Related Potentials, P300; Evoked | 2001 |
[Treatment of hepatic encephalopathy with flumazenil].
Topics: Clinical Trials as Topic; Flumazenil; Glasgow Coma Scale; Hepatic Encephalopathy; Humans | 1990 |
Flumazenil and hepatic encephalopathy.
Topics: Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; Flumazenil; Hepatic Encephalopathy; | 1989 |
57 other studies available for flumazenil and Hepatic Encephalopathy
| Article | Year |
|---|---|
Delayed-onset hepatic encephalopathy induced by zolpidem: a case report.
Topics: Aged; Delayed-Action Preparations; Female; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Huma | 2008 |
Hemoglobin metabolites mimic benzodiazepines and are possible mediators of hepatic encephalopathy.
Topics: Animals; Benzodiazepines; Binding Sites; Cells, Cultured; Cerebral Cortex; Electrophysiology; Flumaz | 2003 |
Hepatic encephalopathy: nomenclature, pathogenesis and treatment.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bromocriptine; Dipeptides; Dopamine Agonists; Electroencep | 2003 |
Normal coupling of brain benzodiazepine and neurosteroid modulatory sites on the GABA-A receptor complex in human hepatic encephalopathy.
Topics: Adult; Aged; Aged, 80 and over; Brain; Female; Flumazenil; Flunitrazepam; Hepatic Encephalopathy; Hu | 2003 |
Increased brain concentrations of endogenous (non-benzodiazepine) GABA-A receptor ligands in human hepatic encephalopathy.
Topics: Adult; Aged; Aged, 80 and over; Allosteric Regulation; Animals; Benzodiazepines; Binding Sites; Bind | 2004 |
Differential effects of ammonia on the benzodiazepine modulatory site on the GABA-A receptor complex of human brain.
Topics: Ammonia; Binding Sites; Binding, Competitive; Brain; Cell Membrane; Dose-Response Relationship, Drug | 2005 |
An interaction between benzodiazepines and neuroactive steroids at GABA A receptors in cultured hippocampal neurons.
Topics: Affinity Labels; Allosteric Regulation; Animals; Azides; Benzodiazepines; Cells, Cultured; Chloride | 2006 |
First clinical investigation of the benzodiazepine antagonist Ro 15-1788 in comatose patients.
Topics: Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Coma; Diagnosis, Differential; | 1983 |
Flumazenil in the treatment of hepatic encephalopathy in children with fulminant liver failure.
Topics: Child; Child, Preschool; Electroencephalography; Flumazenil; Hepatic Encephalopathy; Humans; Infant; | 1995 |
Detection of benzodiazepine in hepatic encephalopathy.
Topics: Benzodiazepines; False Negative Reactions; Flumazenil; Hepatic Encephalopathy; Humans | 1995 |
Flumazenil for hepatic coma: the elusive wake-up call?
Topics: Cross-Over Studies; Double-Blind Method; Flumazenil; Hepatic Encephalopathy; Humans; Liver Cirrhosis | 1994 |
Flumazenil as a diagnostic test for latent hepatic encephalopathy.
Topics: Flumazenil; Hepatic Encephalopathy; Humans | 1994 |
Flumazenil as a diagnostic tool in the differential diagnosis of coma in a critically ill patient.
Topics: Aged; Bacterial Infections; Coma; Critical Illness; Diagnosis, Differential; Diazepam; Flumazenil; H | 1994 |
[Chronic hepatic encephalopathy treated by long-term intravenous administration of flumazenil in ambulatory care].
Topics: Ambulatory Care; Chronic Disease; Esophageal and Gastric Varices; Flumazenil; GABA Modulators; Hepat | 1996 |
Pseudocervical cord syndrome: a deceptive flumazenil reversible manifestation of hepatic encephalopathy.
Topics: Aged; Female; Flumazenil; Hepatic Encephalopathy; Humans; Neck; Spinal Cord Diseases; Syndrome | 1996 |
Flumazenil does not affect the increase in rat hippocampal extracellular glutamate concentration produced during thioacetamide-induced hepatic encephalopathy.
Topics: Animals; Flumazenil; Glutamic Acid; Hepatic Encephalopathy; Hippocampus; Male; Rats; Rats, Sprague-D | 1996 |
Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy.
Topics: Adult; Brain; Carbon Radioisotopes; Female; Flumazenil; Hepatic Encephalopathy; Humans; Male; Middle | 1997 |
Evoked potentials and the effect of flumazenil in patients with liver cirrhosis.
Topics: Adult; Aged; Case-Control Studies; Evoked Potentials, Auditory, Brain Stem; Evoked Potentials, Somat | 1997 |
Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake.
Topics: Animals; Benzodiazepines; Binding, Competitive; Cell Fractionation; Cerebellum; Chronic Disease; Clo | 1998 |
Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil.
Topics: Ammonia; Animals; Benzodiazepines; Chronic Disease; Disease Models, Animal; Dogs; Electroencephalogr | 1998 |
Flumazenil and hepatic encephalopathy.
Topics: Benzodiazepines; Flumazenil; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoh | 1999 |
[Flumazenil and hepatic failure].
Topics: Antidotes; Diagnosis, Differential; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Humans | 2000 |
Hepatic Encephalopathy.
Topics: Adult; Bromocriptine; Dietary Proteins; Digestive System; Flumazenil; Gastrointestinal Agents; Goals | 2001 |
[Chronic liver diseases. The nihilism has gone].
Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; | 2001 |
[Results of displacement studies on benzodiazepine receptors (123I-iomazenil and flumazenil)].
Topics: Flumazenil; Hepatic Encephalopathy; Humans; Iodine Radioisotopes; Receptors, GABA-A; Tomography, Emi | 1992 |
Flumazenil-induced psychotic disorder in hepatic encephalopathy.
Topics: Adult; Female; Flumazenil; Hepatic Encephalopathy; Humans; Psychoses, Substance-Induced | 1992 |
[Flumazenil, hepatic encephalopathy and benzodiazepines].
Topics: Benzodiazepines; Flumazenil; Hepatic Encephalopathy; Humans; Male; Middle Aged; Receptors, GABA-A | 1991 |
Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure.
Topics: Adult; Aged; Benzodiazepines; Brain Chemistry; Chromatography; Diazepam; Flumazenil; Frontal Lobe; g | 1991 |
The effects of benzodiazepine-receptor antagonists and partial inverse agonists on acute hepatic encephalopathy in the rat.
Topics: Animals; Azides; Benzodiazepines; Benzodiazepinones; Electroencephalography; Evoked Potentials, Visu | 1991 |
Benzodiazepine receptor ligands and hepatic encephalopathy: further unfolding of the GABA story.
Topics: Animals; Azides; Benzodiazepines; Benzodiazepinones; Brain; Central Nervous System; Flumazenil; gamm | 1991 |
Beneficial effect of pharmacological modulation of the GABAA-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy.
Topics: Animals; Azides; Behavior, Animal; Benzodiazepines; Benzodiazepinones; Coma; Flumazenil; Hepatic Enc | 1991 |
The contribution of endogenous benzodiazepine receptor ligands to the pathogenesis of hepatic encephalopathy.
Topics: Animals; Brain; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, | 1991 |
Gamma-aminobutyric acid (GABAA) receptor-function in a rat model of hepatic encephalopathy.
Topics: Animals; Cerebral Cortex; Chlorides; Disease Models, Animal; Flumazenil; Hepatic Encephalopathy; Rad | 1990 |
[Flumazenil for the assessment of the degree of hepatic encephalopathy].
Topics: Adult; Flumazenil; Hepatic Encephalopathy; Humans; Male | 1991 |
Persisting benzodiazepine metabolites responsible for the reaction to the benzodiazepine antagonist flumazenil in patients with hepatic encephalopathy.
Topics: Benzodiazepines; Chlordiazepoxide; Chromatography, High Pressure Liquid; Flumazenil; Hepatic Encepha | 1991 |
[The quantitative electroencephalogram in a case of acute hepatic encephalopathy treated with flumazenil].
Topics: Acute Disease; Electroencephalography; Female; Flumazenil; Hepatic Encephalopathy; Humans | 1991 |
Benzodiazepine antagonist in the treatment of human hepatic encephalopathy.
Topics: Benzodiazepines; Coma; Evoked Potentials, Somatosensory; Flumazenil; Hepatic Encephalopathy; Humans; | 1990 |
[Treatment of acute hepatic encephalopathy with flumazenil].
Topics: Acute Disease; Flumazenil; Glasgow Coma Scale; Hepatic Encephalopathy; Humans; Liver Cirrhosis, Alco | 1990 |
Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands.
Topics: Animals; Azides; Benzodiazepines; Disease Models, Animal; Electrophysiology; Evoked Potentials, Visu | 1990 |
[Flumazenil in the treatment of hepatic encephalopathy].
Topics: Aged; Flumazenil; Hepatic Encephalopathy; Humans | 1990 |
Flumazenil does not improve hepatic encephalopathy associated with acute ischemic liver failure in the rabbit.
Topics: Acute Disease; Animals; Dose-Response Relationship, Drug; Electroencephalography; Flumazenil; Hepati | 1990 |
Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil.
Topics: Adult; Benzodiazepines; Evoked Potentials; Female; Flumazenil; Hepatic Encephalopathy; Humans | 1989 |
[Evaluation of the therapeutic effect of flumazenil in hepatic encephalopathy using cerebral cartography].
Topics: Acute Disease; Aged; Brain Mapping; Chronic Disease; Drug Evaluation; Female; Flumazenil; Hepatic En | 1989 |
[Acute effect of flumazenil in refractory hepatic encephalopathy].
Topics: Adult; Flumazenil; Hepatic Encephalopathy; Humans; Middle Aged | 1989 |
Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans.
Topics: Adult; Aged; Arousal; Electroencephalography; Female; Flumazenil; Hepatic Encephalopathy; Humans; Ma | 1989 |
GABAA receptor complex in an experimental model of hepatic encephalopathy: evidence for elevated levels of an endogenous benzodiazepine receptor ligand.
Topics: Animals; Binding, Competitive; Brain; Cell Membrane; Cerebellum; Cerebral Cortex; Disease Models, An | 1989 |
Evidence for the presence of a benzodiazepine receptor binding substance in cerebrospinal fluid of a rabbit model of hepatic encephalopathy.
Topics: Aminocaproates; Animals; Binding, Competitive; Flumazenil; GABA-A Receptor Antagonists; Galactosamin | 1989 |
[Electroencephalographic study of the effect of a benzodiazepine antagonist in hepatic encephalopathy].
Topics: Adult; Aged; Electroencephalography; Female; Flumazenil; Hepatic Encephalopathy; Humans; Male; Middl | 1989 |
[GABA-benzodiazepine receptor complex: therapeutic role of benzodiazepine antagonists].
Topics: Aged; Female; Flumazenil; Hepatic Encephalopathy; Humans; Male; Middle Aged; Receptors, GABA-A | 1989 |
Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABAA-benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure.
Topics: Animals; Bicuculline; Evoked Potentials, Visual; Flumazenil; Hepatic Encephalopathy; Organophosphoru | 1987 |
Treatment of hepatic encephalopathy (HE) with the benzodiazepine antagonist flumazenil: a pilot study.
Topics: Adult; Drug Evaluation; Female; Flumazenil; Hepatic Encephalopathy; Humans; Male; Middle Aged; Recep | 1988 |
Effect of flumazenil in hepatic encephalopathy.
Topics: Adult; Female; Flumazenil; Hepatic Encephalopathy; Humans; Male; Middle Aged; Receptors, GABA-A | 1988 |
Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy.
Topics: Animals; Benzodiazepines; Flumazenil; Flunitrazepam; GABA Antagonists; Galactosamine; Hepatic Enceph | 1988 |
Reversal of hepatic coma by benzodiazepine antagonist (Ro 15-1788)
Topics: Adult; Benzodiazepinones; Convulsants; Female; Flumazenil; Hepatic Encephalopathy; Humans; Middle Ag | 1985 |
Reversal of hepatic coma with flumazenil with improvement in visual evoked potentials.
Topics: Adult; Evoked Potentials, Visual; Female; Flumazenil; Hepatic Encephalopathy; Humans | 1988 |
Improvement of hepatic encephalopathy treated with flumazenil.
Topics: Acute Disease; Adolescent; Adult; Aged; Brain; Child; Chronic Disease; Evoked Potentials, Somatosens | 1988 |
Ro 15-1788 and hepatic failure.
Topics: Acetaminophen; Adult; Female; Flumazenil; Hepatic Encephalopathy; Humans | 1988 |